Section 47
Chapter 46,965

Pharmacoeconomics and health policy. Current applications and prospects for the future

Greenberg, P.E.; Arcelus, A.; Birnbaum, H.G.; Cremieux, P.Y.; LeLorier, J.; Ouellette, P.; Slavin, M.B.

Pharmacoeconomics 16(5 Part 1): 425-432


ISSN/ISBN: 1170-7690
PMID: 10662390
DOI: 10.2165/00019053-199916050-00001
Accession: 046964811

The use of pharmacoeconomic tools has grown dramatically in the past decade as provision of healthcare throughout the industrialised world has required increased cost consciousness. However, pharmacoeconomic analysis has not yet been fully exploited as a conceptual underpinning for public or private health policy decisions. Pharmacoeconomics is likely to become an increasingly important basis for health policy decisions as a number of significant dynamics evolve in the marketplace, including: (i) consumers acting on their growing access to information and becoming more actively involved in treatment decisions; (ii) payers, providers and patients deepening their interaction and overcoming their traditional (narrow) focus on either costs or benefits alone; and (iii) manufacturers being challenged by other healthcare constituencies as sponsors of cost-based outcomes studies.

PDF emailed within 0-6 h: $19.90